BARCELONA, Spain—Patients with ACS who underwent PCI after a protocol switch to ticagrelor-based dual antiplatelet therapy (DAPT) did not have better clinical outcomes than those who were treated when ...
DES PLAINES, IL-- The results of a study conducted by researchers from Indiana University School of Medicine may not support troponin testing for acute coronary syndrome (ACS) in selected elderly ...
Please provide your email address to receive an email when new articles are posted on . In patients with ACS who had angioplasty and stenting, ticagrelor monotherapy after 1 month reduced bleeding vs.
Patients endure heavy medication complexity following hospital discharge for acute coronary syndrome. Objectives: Cardioprotective medications improve outcomes following acute coronary syndromes (ACS) ...
INDIANAPOLIS and TOKYO, Aug. 26, 2012 /PRNewswire/ -- Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) today announced data from the TRILOGY ACS study, a phase III ...
WASHINGTON, D.C, (April 28, 2021) - An analysis of the prospective Fuwai PCI Registry, confirms long-term dual antiplatelet therapy (DAPT) is an optimal treatment option for acute coronary syndrome ...
During the Late Breaking Science Session at the European Society of Cardiology (ESC CONGRESS 2017) in Barcelona, Dr. Pim Tonino (interventional cardiologist, Heart center Catharina Hospital, Eindhoven ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results